Silexion Therapeutics Corp (SLXN)

Currency in USD
0.146
+0.003(+2.32%)
Real-time Data·
Advertisement
Trading near 52-week Low
SLXN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1400.170
52 wk Range
0.14033.500
Key Statistics
Prev. Close
0.142
Open
0.142
Day's Range
0.14-0.17
52 wk Range
0.14-33.5
Volume
678.58K
Average Volume (3m)
10.09M
1-Year Change
-99.5576%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLXN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.000
Upside
+3,324.66%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Silexion Therapeutics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.000
(+3,324.66% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Hold---Downgrade29/07/2026
Litchfield Hills Research
Buy6.00+4,095.80%-New Coverage15/12/2025

Earnings

Latest Release
14/08/2026
EPS / Forecast
-5.17 / -13.10
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare SLXN to Peers and Sector

Metrics to compare
SLXN
Peers
Sector
Relationship
P/E Ratio
−0.1x−1.0x−0.3x
PEG Ratio
-0.000.00
Price/Book
19.3x0.0x2.6x
Price / LTM Sales
-3.5x2.9x
Upside (Analyst Target)
-1,362.8%62.2%
Fair Value Upside
Unlock23.9%8.6%Unlock

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
33.91K0.61%5.20K
Public Companies & Retail Investors
5.53M99.39%846.64K
Total
5.56M100.00%851.83K

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Hudson River Trading LLC0.27%15,2392
Lincoln Alternative Strategies Llc0.24%13,1252

People Also Watch

1.04
AMOD
+1.96%
0.7000
BENF
-13.15%
0.727
TRUG
-5.53%
0.21
INLF
-21.32%
0.304
GIPR
-6.44%

FAQ

What Is the Silexion Therapeutics (NASDAQ: SLXN) Share Price Today?

The Silexion Therapeutics stock price today is 0.146 USD.

What Stock Exchange Does Silexion Therapeutics (SLXN) Trade On?

Silexion Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Silexion Therapeutics?

The stock symbol (also called a 'ticker') for Silexion Therapeutics is "SLXN."

What Is the Current Silexion Therapeutics Market Capitalisation?

As of today, Silexion Therapeutics (NASDAQ: SLXN) market cap is 811.800K USD.

What Is Silexion Therapeutics's (SLXN) Earnings Per Share (TTM)?

The Silexion Therapeutics EPS is currently -38.75 (Trailing Twelve Months).

When Is the Next Silexion Therapeutics Earnings Date?

Silexion Therapeutics's next earnings report will be released on 18/11/2026.

Is SLXN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Silexion Therapeutics moving averages and other technical indicators, the daily buy/sell signal for SLXN stock is Strong Sell.

How Many Times Has Silexion Therapeutics Stock Split?

Silexion Therapeutics has split 3 times. (See the SLXN stock split history page for full effective split date and price information.)

How Many Employees Does Silexion Therapeutics Have?

Silexion Therapeutics has 14 employees, based on their latest Companies House report.

What is the current trading status of Silexion Therapeutics (NASDAQ: SLXN)?

As of 30/10/2026, Silexion Therapeutics (SLXN) is trading at a share price of 0.146 USD, with a previous close of 0.142 USD. The stock has fluctuated within a day range of 0.140 USD to 0.170 USD, while its 52-week range spans from 0.140 USD to 33.500 USD.

What Is Silexion Therapeutics (SLXN) Price Target According to Analysts?

The average 12-month price target for Silexion Therapeutics is 5.000 USD, with a high estimate of 5 USD and a low estimate of 5 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +3,324.66% Upside potential.

What Is the SLXN Premarket Price?

SLXN's last pre-market stock price is 0.146 USD. The pre-market share volume is 16,000.000, and the stock has decreased by 0.004, or 2.820%.

What Is the SLXN After Hours Price?

SLXN's last after hours stock price is 0.157 USD, the stock has decreased by 0.015, or 10.560%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.